XU Shun-gui, LIU Chun-guang. Study on Incentive Policy for Pediatric Drug Research and Development[J]. Chinese Journal of Pharmacovigilance, 2014, 11(12): 746-748.
[1] WHO. Medicines: medicines for children [EB/OL]. [2010-06-22](2011-04-01).http://www.who.int/mediacentre/factsheets/fs341/en/. [2] CDC.药物:儿童药物实况报道(第341号)[EB/OL]. (2010-06-26)[2011-07-12]http://www.chinacdc.cn/gwxx/201210/t20121026_71033.htm. [3] WHO. Essential medicines for children[EB/OL].(2007-07-02)[2008-11-20].http://www.who.int/childmedicines/en/. [4] WHO.WHOModel lists of Essential Medicines[EB/OL].(2007-10-05)[2013-04-11]http://www.who.int/medicines/publications/essentialmedicines/en/. [5] WHO.WHO Model Formulary for Children[EB/OL]. (2009-10-05)[2010-09-01]http://www.who.int/childmedicines/en/. [6] Association of the British Pharmaceutical Industry .Clinical trials and children's medicines [EB/OL]. (2007-08-20) [2008-10-15].http://www.nottingham.ac.uk/news/expertiseguide/areas/c/clinicaltrials,-of-medicines-for-children.aspx.
[7] EC.children's medicines[EB/OL]. (2006-07-05)[2007-11-10].http://ec.europa.eu/health/human-use/paediatric-medicines/index_
en.htm. [8] Dr Ian Wong,Dimah Sweis. Paediatric Medicines Research in the UK[J].Drug Safety ,2003,26(8):25.
[9] 郑晶心.儿童用英国国家处方集出版[J].国外药讯,2006,2(1):4. [10] 国务院妇女儿童工作委员会. 法国开展儿童用药常识[EB/OL].(2002-01-30)[2003-02-10].www.nwccw.gov.cn/html/. [11] FDA. US case study [EB/OL].(2005-01-05)[2006-06-11].http://www.fda.gov/bbs/topics/NEWS/2005/NEW01280.html. [12] 丁锦希,邓媚,白庚亮美国儿科用药数据保护制度及其对儿童
药物安全的影响分析[J].中国药学杂志,2012,47(10):749. [13] 王晓玲,郭春彦.儿童用药剂型与规格的国内外现状分析[J].中国药学杂志,2013,48(7):1316. [14] 杨志敏,张培培.国外儿童药物审评审批管理现状及特点分析[J].中国药学杂志,2012,47(10):745-747. [15] 杨悦,粟高超.WHO儿童基本药物示范目录与我国基本药物目 录中儿童用药的比较研究[J].中国药房,2011,22(32):2994.